ESR1 and breast cancer: Our lab considered a nexus between PI3K/AKT and ER signaling and the role of this axis in anti-estrogen resistance in late 1990s, even before genomic revolution revealing enrichment of genomic aberrations of PI3K/AKT pathway genes in ERα+ breast cancers.